ISSOIRE, France – ( COMMERCIAL THREAD ) – Regulatory news:

BIOCORP (Paris: ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specializing in the design, development and manufacture of innovative medical devices, today announces its annual results for the fiscal year ended December 31, 2020, as approved by the Board of Directors on April 6.

“2020 has been an extraordinary year in the purest sense of the word. The COVID-related crisis has caused the Company to fear a slowdown in its projects. Fortunately, even if they were delayed for a few months, its development contracts were not called into question. Likewise, there have been no delays or cancellations in the manufacturing and marketing of our medical devices. In the end, and thanks to the strong mobilization of all BIOCORP teams, our production activity was only stopped for 3.5 days over the whole of 2020. Thus, on an industrial level, BIOCORP signed the year lastly, a multitude of technological and commercial partnerships allowing Mallya, a true showcase of our know-how, to prepare in the best conditions its marketing wherever diabetes is going to register a strong increase. More than ever, BIOCORP is the ideal partner for pharmaceutical laboratories looking for breakthrough innovations for the benefit of patients. Finally, from a financial standpoint, strict compliance with our objectives and our growth strategy has enabled the Company to welcome new European shareholders. The capital increase carried out at the end of 2020 with qualified investors gives BIOCORP enhanced resources to meet its major ambitions in the field of digital health ” said Éric Dessertenne, CEO of BIOCORP.

Key financial data at 12/31/2020:

• The turnover reached 8,456 K € in 2020, a very slight increase compared to 2019 (8,447 K €). Note the postponement to 2021 of two milestones initially planned for 2020 for an amount of € 2,250,000.

• In 2020, other operating income amounted to € 20.5K compared to € 823K in 2019. This strong variation is mainly explained by the significant amount of construction work in progress at the end of 2019.

• Operating expenses reached € 10,082,000, up 20.1% compared to 2019. This increase is mainly due to the increase in purchases of raw materials, subcontracting, fees and payroll .

• As a result of these elements, the operating result for 2020 is a loss of € 1,605,000, compared to a profit of € 875,000 for 2019.

• The 2020 financial result, which stands at a net amount of (€ 155K) compared to (€ 158K) in 2019, results mainly from interest on bond issues.

• The Exceptional Result for the financial year amounted to € 267,000 compared to € 81.5,000 at 12/31/2019.

• BIOCORP benefited from the CIR (“Research Tax Credit”) and the CII (“Innovation Tax Credit”) for a total amount of € 251.5K.

• Taking all these elements into account, BIOCORP posted a net loss of (€ 1,242K) against a profit of € 960K in 2019.

• Following the completion of a private placement of € 4.2 million in November 2020 with qualified investors and the obtaining of State Guaranteed Loans (“State Guaranteed Loan”) for an amount of 2 , € 1 million, BIOCORP shows a strong increase in its cash flow. As of December 31, 2020, it amounted to € 4,972K compared to € 2,007K a year earlier.

Highlights 2020:

• Strengthening of the partnership with SANOFI around Mallya smart sensors: payment of a new upfront of 5.25 M € including 9.25 M € additional spread over the period of collaboration.

• Marketing partnership on Mallya with the American iSage RX in the field of digitalization of diabetes.

• Signature of a partnership with Théa Laboratories for the development of innovative digital solutions in the field of ophthalmology.

• Mallya technology distribution agreement with Roche Diabetes Care France.

• Signature of a partnership with the Belgian group AARDEX for the development of intelligent solutions for Precision Medical Adherence.

• First commercial launch of Mallya in Romania and South Africa.

• Successful capital increase by private placement with qualified investors for an amount of 4.2 million euros.

Post-period events:

• Signature of two technological partnerships integrating Mallya with digital applications developed by SocialDiabetes and Heath2Sync deployed respectively in Spain, Mexico, Colombia and Chile, and in Taiwan, Hong Kong, Japan, Malaysia, Singapore, United States and Australia: opening of new high growth markets bringing together more than 850,000 users.

• Co-development agreement with the French company Diabeloop to integrate its automated delivery solutions into Mallya in personalized diabetes management.

Outlook for 2021:

According to Eric Dessertenne: “2020 has revealed our ability to pursue our internationalization strategy through the signing of numerous alliances with leading companies, in particular for the deployment of Mallya. While we are preparing for its large-scale commercial launch, we are also developing new connected solutions for markets other than diabetes and are counting on the signing of a new structuring agreement with a large pharmaceutical group very soon. 2021 promises to be particularly exciting for all our teams and, we hope, very exciting for our shareholders. “

ABOUT BIOCORP

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical devices market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of the injected doses and thus offers better compliance in the treatment of diabetic patients. Available for sale from 2020, Mallya is the spearhead of BIOCORP’s product portfolio in terms of innovative connected solutions. The company has 70 employees. BIOCORP has been listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more information, please visit www.biocorpsys.com .